Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Zoledronate may prevent bone loss in patients with primary malignant glioma.
PURPOSE: This phase II trial is studying how well zoledronate works in preventing
osteoporosis in patients with primary malignant glioma.
Phase:
Phase 2
Details
Lead Sponsor:
Duke University
Collaborators:
National Institute of Neurological Disorders and Stroke (NINDS) Novartis